# Shri Ahimsa Naturals share price today (Shri Ahimsa Naturals Ltd, NSE: SHRIAHIMSA)

> Shri Ahimsa Naturals share price today: ₹398.50 at the NSE close on 3 November 2026, up 63.2% in a year. Shri Ahimsa Naturals (NSE: SHRIAHIMSA) is worth ₹948 crore, trades at a P/E of 32.7 and has closed between ₹222.10 and ₹493.75 over the past 52 weeks. > Shri Ahimsa Naturals Ltd's share price has risen faster than its earnings: +63.2% in a year, against +32.3% for earnings per share. SHRIAHIMSA · Chemicals - Organic · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹398.50 (+63.2% in a year)
- P/E: 32.7× (higher than 95% of the last 1 year)
- Revenue (Mar 2026): ₹63.0 Cr (+14.5% on a year ago)
- Profit (Mar 2026): ₹15.0 Cr (+25.0% on a year ago)
- Operating margin: 28.0% (−2.0 points on a year ago)
- ROCE: 22%, FY26
- ROIC: 14.8%, against a 12.0% cost of capital: +2.8 points
- Profit that came in as cash: 40%, last 3 years

The main question: profits are rising, but only 40% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Shri Ahimsa Naturals share price today? Shri Ahimsa Naturals Ltd's share price was ₹398.50 at the close on 3 November 2026. It has been rising for 79 weeks. That is 12.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹222 and ₹494, and at that close it sat 65% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row. Over the last 1 year the share price moved +170% while the NIFTY 500 moved +8%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Shri Ahimsa Naturals this quarter? Two changes stood out: foreign funds (FIIs) cut their stake for 3 quarters in a row and number of shareholders up 52% in a year. 1. Foreign funds (FIIs) cut their stake for 3 quarters in a row From 3% to 0.3% of the company by the September 2026 quarter. 2. Number of shareholders up 52% in a year 1,457 shareholders in the September 2026 quarter, against 958 a year earlier. ## What are Shri Ahimsa Naturals' latest quarterly results? For January to March 2026 (the quarter ended 31 March 2026), Shri Ahimsa Naturals reported revenue of ₹63.0 crore, up 14.5% from ₹55.0 crore a year earlier, and a profit of ₹15.0 crore, up 25.0% from ₹12.0 crore. ### Shri Ahimsa Naturals results: January to March 2026 against a year earlier

| Measure | January to March 2026 | January to March 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹63.0 crore | ₹55.0 crore | +14.5% |
| Profit | ₹15.0 crore | ₹12.0 crore | +25.0% |
| Earnings per share | ₹6.23 | ₹5.23 | +19.1% |
| Operating margin | 28.0% | 30.0% | −2.0 points |

The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them. (From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.)

## What is the Shri Ahimsa Naturals share price history? Shri Ahimsa Naturals closed at ₹398.50 on 3 November 2026, up 63.2% from ₹244.25 a year earlier (31 October 2025). Its highest weekly close since April 2025 was ₹493.75 on 28 August 2026. ### Shri Ahimsa Naturals share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹398.20 | +0.1% |
| 1 month ago · 1 Oct 2026 | ₹422.50 | −5.7% |
| 6 months ago · 30 Apr 2026 | ₹267.90 | +48.7% |
| 1 year ago · 31 Oct 2025 | ₹244.25 | +63.2% |
| Earliest weekly close in our records · 4 Apr 2025 | ₹147.50 | +170.2% |
| Highest weekly close since April 2025, also the 52-week high · 28 Aug 2026 | ₹493.75 | −19.3% |
| Lowest weekly close since April 2025 · 11 Apr 2025 | ₹140.00 | +184.6% |
| 52-week low (weekly close) · 1 Feb 2026 | ₹222.10 | +79.4% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (90 weekly closes from 4 April 2025 to 3 November 2026.)

## What is the latest news on Shri Ahimsa Naturals? 3 Nov 2026: Shri Ahimsa Naturals closed at ₹398.50, up 0.1% on the week and down 5.7% on the month. Results for January to March 2026: Revenue up 14.5% and profit up 25.0% on a year earlier. ## What dividend does Shri Ahimsa Naturals pay? Shri Ahimsa Naturals has paid no dividend on the NSE since its first NSE close in our records (4 April 2025), the start of the period we checked. No. Shri Ahimsa Naturals Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Shri Ahimsa Naturals on? Shri Ahimsa Naturals is not on any of our India lists this week. ## Is Shri Ahimsa Naturals profitable? Shri Ahimsa Naturals Ltd earned ₹15.0 Cr of net profit in the Mar 2026 quarter, +25.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹29.0 Cr. Over 3 years profit has grown −8.6% a year on average. That is 23.8% of the quarter's revenue. For the full year, FY26 profit was ₹29.0 Cr (+31.8% on the year before). ## How much revenue does Shri Ahimsa Naturals make, and is it growing? Shri Ahimsa Naturals Ltd reported ₹63.0 Cr of revenue in the Mar 2026 quarter, +14.5% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown 5.8% a year on average. The last full year, FY26, came in at ₹123 Cr. FY26 revenue was ₹123 Cr, +28.1% on the year before. Recent pace: the last four quarters grew +31.6% on average, against 5.8% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every ₹100 of sales does Shri Ahimsa Naturals keep? Shri Ahimsa Naturals Ltd's operating margin was 28.0% in the Mar 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 4 years it has been between 29.0% and 48.0%. The latest quarter is below every full year in that period. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is Shri Ahimsa Naturals' profit turning into cash? Over the last 3 years, 40% of Shri Ahimsa Naturals Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹9.0 Cr of operating cash against ₹29.0 Cr of profit. After ₹15.0 Cr of spending on assets, free cash was −₹6.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 40% of profit came in as cash: the cash cycle got 123 days longer between FY23 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 123 days longer. The next section looks at where the cash is stuck. ## Where does Shri Ahimsa Naturals' cash go? Shri Ahimsa Naturals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 277 days in FY26, up from 154 days in FY23. It spent ₹37.0 Cr on assets over the last 3 years. Customers take 86 days to pay, and stock sits for 193 days on average. At FY26 sales of ₹123 Cr, each day of that cycle ties up about ₹0.3 Cr, so roughly ₹93.0 Cr is tied up in the business at any time. FY26: customers took 86 days to pay and stock sat for 193 days, about 6.3 months of sales sitting as stock, for a full cycle of 277 days, longer than FY23's 154. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 193 days. Customers pay about 86 days after that. Suppliers are paid at 2 days. Together that makes the 277-day cycle. Spending on assets: ₹37.0 Cr over the last 3 years, against ₹5.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹18.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Shri Ahimsa Naturals' P/E ratio, and how does it compare with its own history? Shri Ahimsa Naturals Ltd's P/E is 32.7×, near the high end of its own history: higher than 95% of past readings. Its usual P/E (the middle reading) is 21.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +32.3% while the price moved +63.2%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Shri Ahimsa Naturals business getting better or worse? Shri Ahimsa Naturals Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Shri Ahimsa Naturals earn on its capital? Shri Ahimsa Naturals Ltd earned a ROCE of 22% in FY26. Its return on capital used (ROIC) is 2.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 23.6% net margin and 0.56× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 23.6% net margin × 0.56× asset turnover × 1.13× leverage (assets divided by equity) ≈ 14.9% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 14.8% − 12.0% = +2.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 14.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 20.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Shri Ahimsa Naturals have too much debt? Shri Ahimsa Naturals Ltd had ₹20.0 Cr of borrowings against ₹193 Cr of equity in FY26, so its debt is 0.10× its equity. Its operating profit is 36 times its interest bill. Over 3 years borrowings went from ₹3.0 Cr to ₹20.0 Cr. Over the last 3 of those years it spent ₹37.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. ## What is the Shri Ahimsa Naturals shareholding pattern? Foreign institutions cut their stake in Shri Ahimsa Naturals Ltd by 2.8 percentage points over 4 quarters, the biggest change among its owners. Foreign institutions now own 0.3% of the company. Domestic institutions moved −2.7 points over the same period, to 5.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −2.8 points over 4 quarters, to 0.3%; Domestic institutions: −2.7 points over 4 quarters, to 5.9%; Promoters: −0.9 points over 4 quarters, to 67.8%. Why the owners changed: foreign institutions drove it (−2.8 points), together with domestic institutions (−2.7 points). They reduced their stake. ## How far is Shri Ahimsa Naturals from balance-sheet trouble? For Shri Ahimsa Naturals Ltd, the Z-score is 14.11. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 14.11 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Shri Ahimsa Naturals rank in its industry? 56.8 out of 100, rank 19 of 20 in Chemicals - Organic, with 47% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Shri Ahimsa Naturals Ltd scores 56.8 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 19. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 16.5 + 17.2 + 9.7 + 13.4 = 56.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Shri Ahimsa Naturals compared with? Shri Ahimsa Naturals ranks 19 of 20 Chemicals - Organic companies on the 4-Factor Sector Score, with 56.8 out of 100. 1. [Nitta Gelatin India Ltd](https://www.sectoralpha.in/stocks/nitta-gelatin-india-ltd) NITTAGELA · quiet · Most evidence points up · 85% evidence 76.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.4/35 · Revenue 15% · Profit 49.4% · Operating margin change 9 points · 100% evidence Capital efficiency 21.3/25 · ROCE 27.7% · Operating margin 28% · 100% evidence Valuation 13.2/20 · P/E 12.1× · PEG 0.95 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 35.5% · 1 year n/a · 25% evidence · 5 of 12 weeks ahead Exact sum: 30.4 + 21.3 + 13.2 + 12 = 76.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) INDOAMIN · losing its lead · Most evidence points up · 81% evidence 66.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 13.3% · Profit 24.2% · Operating margin change 3 points · 88% evidence Capital efficiency 16.8/25 · ROCE 18.9% · Operating margin 14% · 100% evidence Valuation 19.0/20 · P/E 10.6× · PEG 0.32 · 100% evidence Relative strength 9.5/20 · Lead over its industry n/a · Lead over NIFTY 500 2.3% · 1 year -10.4% · 25% evidence · 4 of 12 weeks ahead Exact sum: 20.8 + 16.8 + 19 + 9.5 = 66.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Valiant Organics Ltd](https://www.sectoralpha.in/stocks/valiant-organics-ltd) VALIANTORG · breaking out · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 1.5% · Profit 100% · Operating margin change 6 points · 83% evidence Capital efficiency 9.0/25 · ROCE 5.5% · Operating margin 18% · 76% evidence Valuation 10.9/20 · P/E 23.2× · PEG n/a · 50% evidence Relative strength 19.8/20 · Lead over its industry 24.1% · Lead over NIFTY 500 48.6% · 1 year 39.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.4 + 9 + 10.9 + 19.8 = 61.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [OCCL Ltd](https://www.sectoralpha.in/stocks/occl-ltd) OCCLLTD · breaking out · Too little evidence to rank firmly · 56% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 40.6% · Profit 100% · Operating margin change 7 points · 83% evidence Capital efficiency 12.3/25 · ROCE 13% · Operating margin 28% · 76% evidence Valuation 11.1/20 · P/E 11× · PEG n/a · 15% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 45.3% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.6 + 12.3 + 11.1 + 12.1 = 59.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) BASF · quiet · Evidence leans up · 71% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 6.5% · Profit 62.4% · Operating margin change 4 points · 88% evidence Capital efficiency 11.7/25 · ROCE 14.5% · Operating margin 10% · 100% evidence Valuation 14.1/20 · P/E 21.4× · PEG n/a · 50% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -13% · 1 year -30.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 23.8 + 11.7 + 14.1 + 7.7 = 57.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Elantas Beck India Ltd](https://www.sectoralpha.in/stocks/elantas-beck-india-ltd) ELANTAS · leader · Evidence leans up · 67% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 18.7% · Profit 35.5% · Operating margin change 1 points · 95% evidence Capital efficiency 18.1/25 · ROCE 21.2% · Operating margin 23% · 76% evidence Valuation 6.5/20 · P/E 54.1× · PEG n/a · 50% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 31.9% · 1 year 33.1% · 25% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 18.1 + 6.5 + 11.8 = 57.1 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 7. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) FINEORG · leader · Evidence leans up · 96% evidence 56.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue 7.1% · Profit 5.8% · Operating margin change 4 points · 88% evidence Capital efficiency 17.8/25 · ROCE 21.5% · Operating margin 25% · 100% evidence Valuation 15.0/20 · P/E 35.3× · PEG 0.58 · 100% evidence Relative strength 9.9/20 · Lead over its industry -7.6% · Lead over NIFTY 500 12.4% · 1 year 13.8% · 100% evidence · 9 of 12 weeks ahead Exact sum: 13.9 + 17.8 + 15 + 9.9 = 56.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 8. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) LXCHEM · quiet · Evidence leans up · 81% evidence 54.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 5.5% · Profit 26% · Operating margin change 7.6 points · 88% evidence Capital efficiency 10.8/25 · ROCE 4.7% · Operating margin 12% · 100% evidence Valuation 13.1/20 · P/E 33.8× · PEG 1.14 · 100% evidence Relative strength 9.2/20 · Lead over its industry n/a · Lead over NIFTY 500 1.8% · 1 year -22% · 25% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 10.8 + 13.1 + 9.2 = 54.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Balaji Amines Ltd](https://www.sectoralpha.in/stocks/balaji-amines-ltd) BALAMINES · quiet · Evidence leans up · 78% evidence 53.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.2/35 · Revenue 11.1% · Profit 41.6% · Operating margin change 10 points · 83% evidence Capital efficiency 13.1/25 · ROCE 11% · Operating margin 25% · 76% evidence Valuation 9.1/20 · P/E 28× · PEG n/a · 50% evidence Relative strength 8.2/20 · Lead over its industry -2.5% · Lead over NIFTY 500 15.2% · 1 year 25.3% · 100% evidence · 6 of 12 weeks ahead Exact sum: 23.2 + 13.1 + 9.1 + 8.2 = 53.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) FAIRCHEMOR · quiet · Evidence leans up · 100% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 17.1% · Profit 100% · Operating margin change 6.2 points · 100% evidence Capital efficiency 7.0/25 · ROCE 3.3% · Operating margin 10% · 100% evidence Valuation 13.0/20 · P/E 32.7× · PEG 0.84 · 100% evidence Relative strength 3.0/20 · Lead over its industry -15.4% · Lead over NIFTY 500 3.2% · 1 year -15.9% · 100% evidence · 9 of 12 weeks ahead Exact sum: 30.3 + 7 + 13 + 3 = 53.3 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -15.9%. 11. [Sigachi Industries Ltd](https://www.sectoralpha.in/stocks/sigachi-industries-ltd) SIGACHI · breaking out · Evidence leans down · 100% evidence 49.4 out of 100 Growth Capital Valuation Relative
12. [GFL Ltd](https://www.sectoralpha.in/stocks/gfl-ltd) GFLLIMITED · breaking out · Evidence leans down · 71% evidence 48.6 out of 100 Growth Capital Valuation Relative
13. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) JYOTIRES · basing · Evidence leans down · 74% evidence 43.7 out of 100 Growth Capital Valuation Relative
14. [Foseco India Ltd](https://www.sectoralpha.in/stocks/foseco-india-ltd) FOSECOIND · leader · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
15. [Shree Ganesh Remedies Ltd](https://www.sectoralpha.in/stocks/shree-ganesh-remedies-ltd) SGRL · breaking out · Evidence leans down · 85% evidence 40.3 out of 100 Growth Capital Valuation Relative
16. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) OAL · leader · Evidence leans down · 74% evidence 36.5 out of 100 Growth Capital Valuation Relative
17. [Gem Aromatics Ltd](https://www.sectoralpha.in/stocks/gem-aromatics-ltd) GEMAROMA · quiet · Too little evidence to rank firmly · 51% evidence 32.2 out of 100 Growth Capital Valuation Relative
18. [Sacheerome Ltd](https://www.sectoralpha.in/stocks/sacheerome-ltd) SACHEEROME · losing its lead · Too little evidence to rank firmly · 36% evidence 58.1 out of 100 Growth Capital Valuation Relative
19. Shri Ahimsa Naturals Ltd this page SHRIAHIMSA · leader · Too little evidence to rank firmly · 47% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.5/35 · Revenue n/a · Profit n/a · Operating margin change -2 points · 15% evidence Capital efficiency 17.2/25 · ROCE 21.7% · Operating margin 28% · 75% evidence Valuation 9.7/20 · P/E 32.8× · PEG n/a · 15% evidence Relative strength 13.4/20 · Lead over its industry 9.8% · Lead over NIFTY 500 30.3% · 1 year 63.7% · 100% evidence · 11 of 12 weeks ahead Exact sum: 16.5 + 17.2 + 9.7 + 13.4 = 56.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 20. [Citurgia Biochemicals Ltd](https://www.sectoralpha.in/stocks/citurgia-biochemicals-ltd) CITURGIA · Too little evidence to rank firmly · 25% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Organic](https://www.sectoralpha.in/sectors/chemicals-organic), all 20 compared on one page. ## Which companies are close to Shri Ahimsa Naturals in size? Shri Ahimsa Naturals is the 12th largest of 20 Chemicals - Organic companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Citurgia Biochemicals, Sigachi Industries and Jyoti Resins and Adhesives. Just below it: Sacheerome, Indo Amines and Valiant Organics. ### Chemicals - Organic companies close in size

1. [Citurgia Biochemicals Ltd](https://www.sectoralpha.in/stocks/citurgia-biochemicals-ltd) ₹1,449 crore
2. [Sigachi Industries Ltd](https://www.sectoralpha.in/stocks/sigachi-industries-ltd) ₹1,007 crore
3. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) ₹1,006 crore
4. Shri Ahimsa Naturals Ltd ₹952 crore
5. [Sacheerome Ltd](https://www.sectoralpha.in/stocks/sacheerome-ltd) ₹922 crore
6. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) ₹865 crore
7. [Valiant Organics Ltd](https://www.sectoralpha.in/stocks/valiant-organics-ltd) ₹864 crore

[All 20 Chemicals - Organic companies, largest first](https://www.sectoralpha.in/sectors/chemicals-organic#all-companies)

### Companies close in size in other industries

1. [Western Carriers (India) Ltd](https://www.sectoralpha.in/stocks/western-carriers-indialtd) ₹960 crore · Logistics
2. [Premier Polyfilm Ltd](https://www.sectoralpha.in/stocks/premier-polyfilm-ltd) ₹953 crore · Plastics - Sheets/Films
3. Shri Ahimsa Naturals Ltd ₹952 crore
4. [GKW Ltd](https://www.sectoralpha.in/stocks/gkw-ltd) ₹950 crore · Miscellaneous
5. [Tembo Global Industries Ltd](https://www.sectoralpha.in/stocks/tembo-global-industries-ltd) ₹950 crore · Trading

## What else do people ask about Shri Ahimsa Naturals? ### What is Shri Ahimsa Naturals's share price today? Shri Ahimsa Naturals Ltd's share price is ₹398.50, +63.2% over the past year. The whole company is worth ₹948 Cr on the market. In the last 52 weeks it traded between ₹222 to ₹494; today it is 65% of the way up from the low, 12.3% above its 200-day average (as of 3 November 2026). ### What were Shri Ahimsa Naturals's latest quarterly results? Shri Ahimsa Naturals Ltd reported revenue of ₹63.0 Cr and net profit of ₹15.0 Cr for the Mar 2026 quarter. Revenue rose 14.5% and profit rose 25.0% compared with a year earlier. Earnings per share were ₹6.23. The operating margin was 28.0%, 2.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Shri Ahimsa Naturals's market cap? Shri Ahimsa Naturals Ltd's market capitalisation is ₹948 Cr at a share price of ₹398.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Shri Ahimsa Naturals performing? Shri Ahimsa Naturals Ltd's share price has been rising for 79 weeks. In its latest quarter, revenue rose 14.5% and profit rose 25.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 14 weeks running (as of 3 November 2026). ### Will Shri Ahimsa Naturals's share price go up? This page does not forecast Shri Ahimsa Naturals Ltd's share price. What it shows instead: the share price is ₹398.50, and it has been rising for 79 weeks. Its P/E of 32.7× is higher than 95% of its own last 2 years (as of 3 November 2026). ### Who owns Shri Ahimsa Naturals? Promoters own 67.8% of Shri Ahimsa Naturals Ltd, foreign institutions 0.3%, domestic institutions 5.9% and the public 26.0% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 2.8 percentage points over 4 quarters (as of 3 November 2026). ### Where is Shri Ahimsa Naturals in its business cycle? Shri Ahimsa Naturals Ltd's FY26 operating margin was 29.0%, against a 4-year range of 29.0% to 48.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 28.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Shri Ahimsa Naturals story? The main question: profits are rising, but only 40% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Shri Ahimsa Naturals a stock worth studying right now? What the numbers show: Shri Ahimsa Naturals Ltd's share price has risen faster than its earnings: +63.2% in a year, against +32.3% for earnings per share. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.